首页> 外文期刊>Advances in Nanoparticles >Preparation and Characterization of Novel Drug-Inserted-Montmorillonite Chitosan Carriers for Ocular Drug Delivery
【24h】

Preparation and Characterization of Novel Drug-Inserted-Montmorillonite Chitosan Carriers for Ocular Drug Delivery

机译:新型药物插入式蒙脱土壳聚糖载体的制备与表征

获取原文
获取外文期刊封面目录资料

摘要

The objective of the study was to investigate the potential of montmorillonite as a sustained carrier in the preparation of drug-loaded nanoparticles for prolonged ocular application. Nanoparticles were prepared by ionic gelation of chitosan with sodium tripolyphosphate (TPP). Betaxolol hydrochloride (BH) was applied as a model drug. TG, FT-IR, TEM, DLS and XRD have been employed in the characterization of drug-encapsulated chitosan-montmorillonite/TPP nanoparticles (CS-MMT/TPP NPs). TEM images showed that the particles were spherical in shape and had a rough surface. The size range of the nanoparticles was between 338 and 585 nm with positive zeta potential values from 24 mV to 36 mV and encapsulation efficiency values ranging from 12.27% to 50.92%. In vitro sustained drug release was observed with the BH-loaded nanoparticles in artificial tears (pH 7.4). The results of FT-IR, TG and XRD showed that the drug was coated with CSMMT/ TPP NPs. In the mucoadhesion studies, an interaction was found between drug-loaded CSMMT/ TPP NPs and mucin, which could enhance precorneal residence time and hence facilitate an effective sustained release. The optimized formulation was determined to be non-irritant and tolerable by modified Draize test. Therefore, the BH-loading CS-MMT/TPP NPs developed are a promising carrier for controlled drug delivery to the eye.
机译:这项研究的目的是研究蒙脱石作为持久载体在制备用于长时间眼用药物的纳米颗粒中的潜力。通过壳聚糖与三聚磷酸钠(TPP)的离子凝胶化制备了纳米颗粒。盐酸倍他洛尔(BH)被用作模型药物。 TG,FT-IR,TEM,DLS和XRD已用于表征药物封装的壳聚糖-蒙脱土/ TPP纳米粒子(CS-MMT / TPP NPs)。 TEM图像显示颗粒为球形并且具有粗糙的表面。纳米颗粒的尺寸范围在338至585nm之间,正ζ电势值为24mV至36mV,包封效率值为12.27%至50.92%。在人工泪液(pH 7.4)中,用BH负载的纳米颗粒观察到体外药物的持续释放。 FT-IR,TG和XRD结果表明该药物被CSMMT / TPP NPs包被。在粘膜粘附研究中,载药的CSMMT / TPP NP与粘蛋白之间存在相互作用,这可以增加角膜前停留时间并因此促进有效的持续释放。通过改良的Draize试验确定优化配方无刺激性和耐受性。因此,开发的BH负载CS-MMT / TPP NP是用于控制药物向眼睛输送的有前途的载体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号